[ASAP] Development of Telmisartan Nanocrystal-Based Dissolving Microneedle for Brain Targeting via Trigeminal Pathway: A Potentially Promising Treatment for Alzheimer’s with an Improved Pharmacokinetic Profile

AI Summary

This article discusses the development of a telmisartan nanocrystal-based dissolving microneedle for brain targeting via the trigeminal pathway. The treatment aims to improve the pharmacokinetic profile in Alzheimer's disease. The use of nanocrystals and microneedles could potentially offer a more effective and targeted therapy for this condition.

Leave a Reply